Patient Enrollment Completed for Phase III Clinical Trial of Akeso’s Cadonilimab in Treatment of Gastric Cancer

HONG KONG, March 14, 2023 /PRNewswire/ — Akeso, Inc. (9926.HK) announced that patient enrollment has been completed for its pivotal Phase III clinical trial for cadonilimab (PD-1/CTLA-4 bi-specific antibody, AK104), the world’s first approved and marketed dual-immune checkpoint…

Leave a Reply

Your email address will not be published. Required fields are marked *